2006 Symposium Highlights
Translational Medicine and Therapeutics:
The Future of Drug Development
May 5-6, 2006
The College of Integrated Life Sciences: an Academic Model for Fostering Translational Research (pdf) Edward Holmes, M.D., Vice Chancellor, UCSD (University of California, San Diego) |
αllb β3 Antagonists As An Example of Translational Medicine Therapeutics (pdf) Barry Coller, M.D., Physician in Chief, Rockefeller University |
Prescribing by Genotype Are We There Yet? (pdf) Alastair Wood, M.D., Associate Dean, Vanderbilt University School of Medicine |
Cell and Gene Therapies: Challenges in Developing Paradigms for Analyzing Novel Therapeutics (pdf) Kathy High, M.D., Ph.D., Investigator, HHMI, University of Pennsylvania School of Medicine |
The Emerging Era of Translational Medicine and Therapeutics Garret FitzGerald, M.D., Director, ITMAT, Chair, Department of Pharmacology, University of Pennsylvania |
Translational Studies in Heart Failure (pdf) Walter Koch, Ph.D., Director, Center for Translational Medicine, Thomas Jefferson University |
Today's Discoveries, Tomorrow's Cures? A Convergence of Cultures (pdf) Ellen Puré, Ph.D., Wistar and Ludwig Institutes |
Integrated Clinical Research Informatics for Translational Medicine and Therapeutics (pdf) J. Richard Landis, Ph.D., Professor of Biostatistics, University of Pennsylvania |
The Greater Philadelphia Bioinformatics Alliance: Technology Collaboration for Training and Discovery (pdf) J. Robert Beck, M.D., Vice President and Deputy Director of Population Science, Fox Chase Cancer Center |
Fostering Innovation: A Government Perspective (pdf) Mary Harney, TD, Tánaiste and Minister for Health and Children, Government of Ireland |
FDA's Critical Path Initiative and Translational Research (pdf) Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA |
Revitalising Clinical Investigation, Who, How and Where? (pdf) Sir Colin Dollery, M.D., Senior Advisor, GlaxoSmithKline |
Making Pharma Sector Investment More Attractive — Why the Business Model Needs to Change? (pdf) Sophia Tickell, BA, Director of Pharma Futures II, and Chair, SustainAbility |
Improving Dugs and Development by Technology (pdf) Thomas Caskey, M.D., Managing Director, Cogene Ventures |
VEGF Trap in Clinical Trials Today, and VelociGene Coupled with VelocImmune for Drug Trials of Tomorrow (pdf) George Yancopoulis, M.D., Ph.D., Chief Scientific Officer, Regeneron |
Labors of Love: Science Serving the Public Good (pdf) Jerome Strauss, M.D., Ph.D., Dean VCU School of Medicine, Virginia Commonweath University |